|
1
|
Huang X, Cortes J and Kantarjian H:
Estimations of the increasing prevalence and plateau prevalence of
chronic myeloid leukemia in the era of tyrosine kinase inhibitors
therapy. Cancer. 118:3123–3127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J,
Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, et al: A therapeutically
targetable mechanism of BCR-ABL-independent imatinib resistance in
chronic myeloid leukemia. Sci Transl Med. 6:252ra1212014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hughes TP, Kaeda J, Branford S, Rudzki Z,
Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC,
Goldman JM, et al: Frequency of major molecular responses to
imatinib or interferon alfa plus cytarabine in newly diagnosed
chronic myeloid leukemia. N Engl J Med. 349:1423–1432. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berman E, Jhanwar S, Hedvat C, Arcila ME,
Wahab OA, Levine R, Maloy M, Ma W and Albitar M: Resistance to
imatinib in patients with chronic myelogenous leukemia and the
splice variant BCR-ABL1 (35INS). Leuk Res. 49:108–112. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tabarestani S and Movafagh A: New
developments in chronic myeloid leukemia: Implications for therapy.
Iran J Cancer Prev. 9:e39612016.PubMed/NCBI
|
|
6
|
Wang LX, Wang JD, Chen JJ, Long B, Liu LL,
Tu XX, Luo Y, Hu Y, Lin DJ, Lu G, et al: Aurora A kinase inhibitor
AKI603 induces cellular senescence in chronic myeloid leukemia
cells harboring T315I mutation. Sci Rep. 6:355332016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bixby D and Talpaz M: Seeking the causes
and solutions to imatinib-resistance in chronic myeloid leukemia.
Leukemia. 25:7–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gupta P, Kathawala RJ, Wei L, Wang F, Wang
X, Druker BJ, Fu LW and Chen ZS: PBA2, a novel inhibitor of
imatinib-resistant BCR-ABL T315I mutation in chronic myeloid
leukemia. Cancer Lett. 383:220–229. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Speijer D: Does constructive neutral
evolution play an important role in the origin of cellular
complexity? Making sense of the origins and uses of biological
complexity. Bioessays. 33:344–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Song Y, Shi Y, Carland TM, Lian S, Sasaki
T, Schork NJ, Head SR, Kishi S and Schimmel P: p53-Dependent DNA
damage response sensitive to editing-defective tRNA synthetase in
zebrafish. Proc Natl Acad Sci USA. 113:pp. 8460–8465. 2016;
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burger G: Non-functional genes repaired at
the RNA level. C R Biol. 339:289–295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nowell PC: The clonal evolution of tumor
cell populations. Science. 194:23–28. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gerlinger M, Rowan AJ, Horswell S, Math M,
Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N,
Stewart A, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schwer B, Wei PC, Chang AN, Kao J, Du Z,
Meyers RM and Alt FW: Transcription-associated processes cause DNA
double-strand breaks and translocations in neural stem/progenitor
cells. Proc Natl Acad Sci USA. 113:pp. 2258–2263. 2016; View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ceccaldi R, Rondinelli B and D'Andrea AD:
Repair pathway choices and consequences at the double-strand break.
Trends Cell Biol. 26:52–64. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li JB and Church GM: Deciphering the
functions and regulation of brain-enriched A-to-I RNA editing. Nat
Neurosci. 16:1518–1522. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Witzany G: The agents of natural genome
editing. J Mol Cell Biol. 3:181–189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grewe F, Viehoever P, Weisshaar B and
Knoop V: A trans-splicing group I intron and tRNA-hyperediting in
the mitochondrial genome of the lycophyte Isoetes engelmannii.
Nucleic Acids Res. 37:5093–5104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Castandet B, Choury D, Bégu D, Jordana X
and Araya A: Intron RNA editing is essential for splicing in plant
mitochondria. Nucleic Acids Res. 38:7112–7121. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang X, Maity T, Kashyap MK, Bansal M,
Venugopalan A, Singh S, Awasthi S, Marimuthu A, Jacob HK Charles,
Belkina N, et al: Quantitative tyrosine phosphoproteomics of
Epidermal Growth Factor Receptor (EGFR) tyrosine kinase
inhibitor-treated lung adenocarcinoma cells reveals potential novel
biomarkers of therapeutic response. Mol Cell Proteomics.
16:891–910. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McGranahan N and Swanton C: Clonal
heterogeneity and tumor evolution: Past, present, and the future.
Cell. 168:613–628. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gao D, Herman JG and Guo M: The clinical
value of aberrant epigenetic changes of DNA damage repair genes in
human cancer. Oncotarget. 7:37331–37346. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
King MC, Marks JH and Mandell JB; New York
Breast Cancer Study Group, : Breast and ovarian cancer risks due to
inherited mutations in BRCA1 and BRCA2. Science. 302:643–646. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu H, Li H, Cui Y, Xiao W, Dai G, Huang J
and Wang C: The mRNA level of MLH1 in peripheral blood is a
biomarker for the diagnosis of hereditary nonpolyposis colorectal
cancer. Am J Cancer Res. 6:1135–1140. 2016.PubMed/NCBI
|
